Circulating metabolites and lipids reflect patient mutational heterogeneity. Unbiased metabolomics and lipidomics of AML plasma samples at diagnosis were categorized based on patient mutational status, and t test was performed to identify significantly different metabolites (A) and lipids (B). Pathway enrichment of significantly changed metabolites (C) and lipids (D) were also assessed across patient mutations. Mutations for which multiple testing methods were used for mutation detection (FLT3 and NPM1) are represented as 1 group. FDR, false discovery rate.